Lilly losing dominance in diabetes treatment
Eli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses on other products that have begun to sap the drugmaker’s sales.
Eli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses on other products that have begun to sap the drugmaker’s sales.
After spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West Lafayette-based drug developer is in better position than ever.
Dr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.
It looks like Arcadia Resources Inc.’s DailyMed pharmacy business will live on—but under the wing of Walgreen Co. instead of on its own.
Officials say an as-yet-unnamed drug company is looking to take over much of the former Pfizer Inc. complex near Terre Haute that had about 800 workers before it was shut down.
The Indianapolis-based partnership is among 32 in the U.S. chosen for a model program designed to provide more coordinated care for people served by Medicare.
As it is in the rest of the country, the 2010 health reform in Indiana continues to be unpopular, unlikely to be repealed and uncertain to put a dent in health spending, according to a poll of Hoosiers released last week by Ball State University.
Franciscan Alliance’s Indianapolis-area hospitals, along with more than 700 physicians, have been named one of the nation’s first 32 accountable care organizations.
Independent health care facilities, like Body One Physical Therapy, are seeing referrals from physicians beginning to slacken as more and more doctors become employees of hospitals. The hospitals request that doctors send patients to their in-house physical therapy practices.
The new hires could be important following last year’s legislative session, in which state lawmakers passed a law to cut off Medicaid funding to groups that offer abortions.
Pharmacy benefits manager Express Scripts Inc. said Tuesday it is in the middle of a contract dispute with WellPoint Inc., one of the biggest health insurers in the United States.
Shares of Endocyte Inc. plummeted more than 60 percent Tuesday morning after clinical trial results showed the company’s experimental ovarian cancer drug led to shorter survival times than treatment with a standard cancer drug.
In 1993, only 3.8 percent of Hoosier adults had full-blown diabetes, compared with 9.8 percent today.
Health insurer expects enrollment in its health plan to grow 30 percent next year, to nearly 21,000. And then it expects growth of another 40 percent.
Health costs remain the No. 1 cause of personal bankruptcy and the largest, most uncontrollable element for businesses. This is unsustainable.
Eli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s experimental Alzheimer’s drug could double the share price.
Carmel resident David Wasilewski has launched WhatNext, a website that uses algorithms to make it easier for cancer patients to connect with others in similar circumstances. Wasilewski, 39, spent eight years as chief operating officer of the Spanx line of body shapers and did health care consulting before that. In addition to helping patients, he thinks WhatNext can become a way for health care organizations share their expertise with patients in need.
In spite of all the consolidation lately among hospitals, Community Health CEO Bryan Mills says the future of hospital systems will hinge more on partnerships like the one Community struck last week on its rehab hospital.
The Obama administration on Friday let stand an earlier rule that said brokers’ fees will have to count toward a 15-percent to 20-percent cap on administrative expenses placed on insurance plans by the 2010 health overhaul.
Takeda Pharmaceutical Co. and marketing co-partner Eli Lilly and Co. may face as many as 10,000 lawsuits in U.S. courts over allegations that their Actos diabetes drug causes bladder cancer.